Humacyte Management
Management criteria checks 4/4
Humacyte's CEO is Laura Niklason, appointed in Jan 2004, has a tenure of 21.33 years. total yearly compensation is $905.44K, comprised of 67.6% salary and 32.4% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $616.93K. The average tenure of the management team and the board of directors is 4.1 years and 3.8 years respectively.
Key information
Laura Niklason
Chief executive officer
US$905.4k
Total compensation
| CEO salary percentage | 67.64% |
| CEO tenure | 21.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.1yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Is Humacyte (NASDAQ:HUMA) A Risky Investment?
May 21
Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)
Mar 24Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning
Jan 08Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)
Dec 23Humacyte: FDA Waiting Game Bleeding Company Dry
Dec 14Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
Sep 24Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Aug 16Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Jul 17Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation
Jun 05Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
May 14Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Feb 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$80m |
| Dec 31 2024 | US$905k | US$612k | -US$149m |
| Sep 30 2024 | n/a | n/a | -US$153m |
| Jun 30 2024 | n/a | n/a | -US$140m |
| Mar 31 2024 | n/a | n/a | -US$106m |
| Dec 31 2023 | US$3m | US$604k | -US$111m |
| Sep 30 2023 | n/a | n/a | -US$89m |
| Jun 30 2023 | n/a | n/a | -US$89m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$2m | US$500k | -US$12m |
| Sep 30 2022 | n/a | n/a | US$34m |
| Jun 30 2022 | n/a | n/a | US$28m |
| Mar 31 2022 | n/a | n/a | -US$26m |
| Dec 31 2021 | US$11m | US$500k | -US$26m |
| Sep 30 2021 | n/a | n/a | -US$85m |
| Jun 30 2021 | n/a | n/a | -US$71m |
| Mar 31 2021 | n/a | n/a | -US$69m |
| Dec 31 2020 | US$619k | US$75k | -US$67m |
Compensation vs Market: Laura's total compensation ($USD905.44K) is below average for companies of similar size in the US market ($USD2.71M).
Compensation vs Earnings: Laura's compensation has been consistent with company performance over the past year.
CEO
Laura Niklason (61 yo)
Dr. Laura E. Niklason, M.D., Ph D., serves as President and Chief Executive Officer at Humacyte, Inc. since November 2020. She founded Humacyte, Inc. in 2004 and served as its Chief Scientist from 2005 to...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.3yrs | US$905.44k | 0.16% $ 616.9k | |
| CFO, Chief Corporate Development Officer & Treasurer | 4.5yrs | US$704.19k | 0.027% $ 107.8k | |
| Chief Operating Officer | 6yrs | US$653.21k | 0% $ 0 | |
| Chief People Officer | no data | no data | no data | |
| Chief Commercial Officer | 3.8yrs | no data | 0.014% $ 55.7k | |
| Chief Medical Officer | 3.1yrs | US$1.53m | 0.0048% $ 19.0k | |
| Chief Regulatory Officer | 2.7yrs | no data | no data |
Experienced Management: HUMA's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.3yrs | US$905.44k | 0.16% $ 616.9k | |
| Independent Director | 19.9yrs | US$336.00k | 0.042% $ 163.3k | |
| Director | 20.3yrs | US$331.00k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$331.00k | 0% $ 0 | |
| Independent Director | no data | US$336.00k | 0% $ 0 | |
| Independent Chairman of the Board | 9.7yrs | US$356.00k | 0.059% $ 230.8k | |
| Independent Director | 3.8yrs | US$338.50k | 0.021% $ 83.4k | |
| Independent Director | 2.9yrs | US$331.00k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$331.00k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$331.00k | 0.0015% $ 6.1k | |
| Independent Director | less than a year | US$449.25k | no data | |
| Independent Director | less than a year | US$449.25k | no data |
Experienced Board: HUMA's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 13:36 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Humacyte, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Michael Gorman | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |